Oxford BioMedica plc - Sales Analysis Snapshot

Business Description
This Report provides a comprehensive Sales & Margin summary analysis for Oxford BioMedica plc Tabular results include up to a ten-year history on Sales, EBITDA (Earnings before Interest, Taxes, Depreciation and Amortization), Income before Extraordinary Items and number of Employees. Additional ratios are included for sales growth, earnings and income as a percent of sales and Sales per Employee.

Oxford BioMedica plc. The Group's principal activity is researching and developing genebased medicines and therapeutic vaccines based on a broad technology platform. The Group's development pipeline comprises four products in clinical development and a late-stage preclinical candidate. The lead product is TroVax,a therapeutic vaccine that has potential application in a range of tumour types. The product is designed to stimulate a specific anti-cancer immune response against a protein called 5T4. The Group's other products are Hi-8 MEL, MetXia, ProSavin and RetinoStat. The Group operates in the United Kingdom and the United States of America.

Not the Report you are looking for? Click here for more browsing options.

view sample Single Report

view sample All Basic Reports

Layout and Content of a Typical Report